Login to Your Account



Clovis Oncology's PARP Pill Procurement Plumps Pipeline

By Catherine Shaffer


Monday, June 6, 2011
Clovis Oncology Inc. picked up another clinical-stage compound to add to its pipeline of cancer products. The Boulder, Colo.-based company will pay an undisclosed upfront fee to Pfizer Inc., plus potential milestones of $255 million, in exchange for the right to develop and commercialize the drug. In turn, Pfizer Venture Investments will make an equity investment in Clovis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription